On 27 May 2026, Italy confirmed a rabies case in a dog in Vittorio Veneto, Treviso Province, Veneto Region. Investigations revealed that the dog had been illegally imported into Italy in December 2025 following a family member’s tourist trip to Morocco.
This is the first reported rabies case in northeastern Italy in approximately 15 years and has triggered enhanced public health and veterinary control measures in Vittorio Veneto including 32 individuals receiving post-exposure prophylaxis (PEP).
As of 20 March 2026, the Campania region of Italy has recorded at least 154 hepatitis A cases (+21 within 24 hours) since the beginning of the year. The increase in cases is suspected to be linked to contamination of bivalve molluscs, prompting intensified control measures across the entire bivalve supply chain.
Cotugno Hospital, the regional reference center for infectious diseases in Naples, is managing 54 hospitalized hepatitis A patients as of 22 March 2026, including eight new admissions to the emergency department on that day alone.
In response, Naples Mayor Gaetano Manfredi issued an emergency ordinance banning the consumption of raw shellfish and related molluscs in all public establishments.
Follow local advices. Practice excellent hand hygiene and food safety and do not eat raw und undercooked sea food. Seek medical advice if you develop symptoms. Vaccination against hepatitis A is recommended for people for persons at risk, see SOP hepatitis A at www.healthytravel.ch PRO version as well.
Regional health authorities have also ordered the strengthening and expansion of the free hepatitis A vaccination program for those most at risk: health and social health personnel, food supply chain workers, fragile patients and pediatric population, in relation to epidemiological risk and exposure.
General precautions:
Recommended vaccinations:
If you are sick:
Locally acquired mpox cases have now been confirmed in four countries. Spain reported its first such case on 10 October 2025, and the Netherlands on 17 October 2025. These have been followed by additional cases reported in Italy (2) and Portugal (1).
These new cases have been reported among men, some of whom identify themselves as men who have sex with men, with no recent travel history to mpox-endemic areas.
This development is distinct from the previously reported travel-associated clade Ib cases between August 2024 and October 2025, mostly among returning travellers from mpox-endemic areas outside of the EU.
Risk very low for general populations but moderate for at risk groups.
France reported 82 new locally acquired chikungunya cases in the past week, bringing the total to 383 across 37 clusters. Twenty-six clusters remain active, with the largest in Bergerac (54 cases).
Italy reported 60 new locally acquired chikungunya cases, raising the total to 167 across four clusters. Three clusters remain active, with the largest in Carpi–San Prospero–Soliera (134 cases)
Active (red) and closed (yellow) clusters as of 10 Sept 2025, for updates, see ECDC dashboard.
Since the beginning of 2025, and as of 20 August 2025, nine countries in Europe have reported human cases of West Nile virus infection: Albania, Bulgaria, France, Greece, Hungary, Italy, Romania, Serbia and Spain. Currently, 67 areas are known to be affected.
For updates, see ECDC LINK.
The following precautions are recommended:
If you have visited a West Nile fever transmission area, do not donate blood for at least 28 days after returning.
Within one week, Italy reported more than 100 additional West Nile virus (WNV) cases, bringing the total to 275 confirmed cases with 19 deaths. The outbreak is most severe in the Lazio and Campania regions and is spreading into northern Italy. Neuroinvasive cases are substantial, with 126 reported and an estimated mortality rate of about 15.1%.
More info on outbreaks among equids and birds in Europe is available in the ECDC and EFSA monthly report.
Provinces with proven circulation of WNV in vectors, animals and humans (asymptomatic donors, fever and confirmed neuroinvasive cases):
The following precautions are recommended:
Italy has reported seven deaths from West Nile virus as of 29 Jul 2025 (all in individuals 65 and older and with underlying conditions), with outbreaks emerging in Lazio, Campania, and Piedmont, marking a shift from the traditionally affected northern regions. In response, health authorities have implemented mosquito control measures and restricted blood donations in 31 provinces.
More info on outbreaks among equids and birds in Europe is available in the ECDC and EFSA monthly report.
The following precautions are recommended:
Optimal mosquito protection 24/7, also in cities (also against other mosquito-borne diseases). Vaccination
against dengue is not routinely recommended for residing or traveling in European countries.
Note on vaccination against dengue fever with Qdenga®:
In case of fever:
More locally acquired cases are expected in the summer season.
Optimal mosquito protection 24/7 also in cities (also against other mosquito-borne diseases such as
dengue). The Swiss Expert Committee for Travel Medicine does not recommend chikungunya vaccination for travelers visiting Italy, mainland France or Corsica.
More locally acquired cases are expected in the upcoming summer season.
Optimal mosquito protection 24/7, also in cities (also against other mosquito-borne diseases such as dengue). The Swiss Expert Committee for Travel Medicine does not recommend chikungunya vaccination for travelers visiting Italy.
Several countries in the European Union have observed an increase in reported cases of hepatis A genotype 1B. In particular, Austria, Czechia and Hungary have observed more reported cases than expected between November 2024 to May 2025.
The increase of HAV infection is mainly affecting adults that are experiencing homeless, people with a drug addiction and people living in poor sanitary conditions. Two genetically closely related clusters of HAV 1b have been identified (cluster a and cluster b).
The chain of transmission is ongoing, and new cases are likely to occur.
Vaccination against hepatitis A is recommended for people visiting friends and relatives in remote rural areas and/or where hygiene conditions are poor as well as for risk persons, see SOP hepatitis A at www.healthytravel.ch PRO version.
The probability of European citizens becoming infected with communicable diseases during the Jubilee 2025 is low if general preventive measures are applied such as
Die Daten zu Masernfällen in der Europäischen Union und im Europäischen Wirtschaftsraum (EU/EWR) in den letzten zwölf Monaten (1. Februar 2024 bis 31. Januar 2025 32‘265 Masernfälle) zeigen einen deutlichen Anstieg der Meldungen im Vergleich zu 2023. Rumänien (27‘568), Italien (1‘097), Deutschland (637), Belgien (551) und Österreich (542) wiesen die höchsten Fallzahlen auf.
Aufgrund der vermehrten Viruszirkulation, werden die Fallzahlen sehr wahrscheinlich im Frühjahr 2025 zunehmen. Die anhaltende Übertragung deutet auf Lücken in der Durchimpfung gegen diese vermeidbare Krankheit hin – sowohl bei Kindern als auch bei Jugendlichen und Erwachsenen.
Lassen Sie Ihren Impfstatus überprüfen!
Alle nach 1963 geborenen Personen, die keinen nachgewiesenen Schutz gegen Masern haben (Antikörper oder 2 nachgewiesene Impfungen), sollten zweimal mit dem MMR-Impfstoff geimpft werden. Im Falle einer Epidemie in der Region oder bei Kontakt mit einem Masernfall wird die Impfung ab einem Alter von 6 Monaten empfohlen.
The data from the latest ECDC annual epidemiologic reports on sexual transmitted diseases (STIs) show the notification rate for confirmed gonorrhea cases in European Union/European Economic Area countries rose by 31% in 2023 compared with 2022 and has risen by 321% since 2014.
Syphilis cases also continue to rise. In 2023, 41’051 confirmed cases were reported in 29 EU/EEA countries, representing a 13% increase compared to 2022, and a doubling compared to 2014.
As of 3 October, 130 locally acquired dengue cases have been reported by the Italian National Public Health Authority. These are 63 more cases than reported in the previous week's update. The newly reported cases were from Marche (51 cases), Emilia Romagna (14 cases) and Lombardy (one case). According to local authorities in the Marche Region, there is a decreasing trend in case numbers reported from Fano.
For 129 cases NUTS2 regions were reported:
An additional case (onset of symptoms 18 August, DENV 2) was reported by the Abruzzo region. However, the place of infection is currently under investigation as the infection may have occurred in another region.
Prevention: Optimal mosquito bite protection during the day, also in cities.
In case of fever, apply paracetamol products and hydration. If you have a fever, avoid taking medications containing acetylsalicylic acid (e.g., Aspirin®), as this can increase the risk of bleeding during a dengue infection. However, do not stop taking medications containing acetylsalicylic acid if it is already part of your regular treatment for an underlying condition.
Note on vaccination against dengue fever with Qdenga®:
The Swiss Expert Committee for Travel Medicine (ECTM) recommends a vaccination with Qdenga® only for travelers from 6 years old who have evidence of previous dengue infection and who will be exposed in a region with significant dengue transmission. For details, see ECTM Statement.
In 2024 and as of 2 October 2024, 18 countries in Europe have reported 1’202 locally acquired human cases of West Nile Virus (WNV) infection with known place of infection. The earliest and latest date of onset were respectively on 1 March 2024 and 26 September 2024.
Locally acquired cases were reported by Italy (422), Greece (202), Spain (114), Albania (102), Hungary (101), Romania (71), Serbia (53), Austria (34), Türkiye (30), France (27), Croatia (20), Germany (8), Slovenia (5), Kosovo (4), Slovakia (4), Bulgaria (2), North Macedonia (2) and Czechia (1).
In Europe, 88 deaths were reported by Greece (31), Italy (16), Albania (13), Romania (10), Spain (10), Bulgaria (2), Serbia (2), Türkiye (2), France (1) and North Macedonia (1).
Case numbers reported this year are above the mean monthly case count for the past 10 years. During the same period in 2023, 681 cases had been reported. However, numbers are lower than in 2018, when 1 728 cases had been reported by this time of year.
Distribution of locally acquired human West Nile virus infections in 2024 till 2 October 2024:
Of note, further regions of infection were reported in 2023.
The following precautions are recommended:
Since the first week of August and as of 11 September 2023, 19 locally acquired dengue fever cases have been detected in the Lombardy (14) and Lazio (5) regions in Italy. The cases are grouped in three clusters:
All cases were laboratory confirmed by PCR and all cases have recovered or are improving.
A DENV-1 serotype virus was identified in the cases in Lombardy and in the metropolitan city of Rome, Lazio region. Epidemiological investigations have not identified any link between the cases in Lombardy and the cases identified in the Lazio region.
A DENV-3 serotype was detected in the cluster of cases in the province of Latina, Lazio region, indicating that this outbreak is independent from the other two in Italy.
Response and control measures are being implemented by Italian public health authorities. These include case finding, vector control activities, information to healthcare providers and the general public, and preventive measures for donors of substances of human origin (e.g. blood and organs).
So far, 146 imported dengue cases have been registered in Italy in 2023, most of them in the Lombardy region (50 imported cases) and Lazio region (28 imported cases).
For more details of the outbreak in Italy, see Rapid Communication of Eurosurveilance.
The risk is low. People who are over 60 years of age, have an underlying disease, or have a weakened immune system are at higher risk for the more severe form of West Nile virus.
The following precautions are recommended:
If you have visited a West Nile fever transmission area, do not donate blood for at least 28 days after your return.
Informazioni generali su morbillo, parotite e rosolia (MOR)
Consultare i seguenti link dell' Ufficio federale della sanità pubblica UFSP:
Consultare il seguente link dell'UFSP:
Informazioni generali sulla varicella e sull’herpes zoster
Depending on the geographical region and the species, ticks may carry and transmit different pathogens. Diseases include the human ehrlichiosis, Lyme disease, tularemia, babesiosis, tick-borne relapsing fever, Rocky Mountain spotted fever, other rickettsioses, some arboviral diseases, and several flaviviruses causing encephalitis such as tick-borne encephalitis (TBE). Some ticks may also cause tick paralysis.
In Europe, commonly transmitted disease by ticks include Lyme disease (borreliosis), tick-borne encephalitis and tularemia.
In the US (and less so in South America) important tick-borne diseases represent babesiosis, anaplasmosis and ehrlichiosis, Powassan disease and severe fever with thrombocytopenia syndrome (STFS).
Other important pathogens transmitted by ticks are bacterial organisms causing rickettsial diseases, which are found throughout the world. Among returned travelers, rickettsial diseases have been estimated to be the fourth most common cause of fever, with symptoms such as rash, abdominal pain, and a dry, black/dark scab at the site of the infecting bite.
Tick-borne diseases may occur worldwide, but distribution is based on geographical location (see map).
Areas with increased risk of TBE include central and eastern Europe and the Baltic and Nordic countries. TBE is also prevalent in Russia all the way from the western border with Europe to its eastern border.
Lyme borreliosis is the most prevalent tick-transmitted infection in temperate areas of Europe, North America and Asia, and its geographic distribution is ever-increasing. Central Europe is the region with the highest tick infection rates (young ticks/nymphs >10%; adult ticks >20%) in Europe, specifically in Austria, Czech Republic, southern Germany, Switzerland, Slovakia and Slovenia.
Babesiosis is found in certain regions of North America and forested areas in Europe and East Asia. Anaplasmosis is common in North America, Europe, and China.
Ehrlichiosis is common in the US, certain areas of Europe, South America, and Africa.
Powassan disease is found in the northeastern US and far eastern Russia, whereas Severe Fever with Thrombocytopenia Syndrome (SFTS) occurs in the US and Asia-Pacific region.
Rickettsial infections are present worldwide. African Tickbite Fever (ATBF) is the most commonly reported rickettsial infection acquired during travel and occurs in southern Africa (especially Botswana, South Africa, and Zimbabwe).Mediterranean Spotted Fever (MSF), reported among returning US and UK travelers, occurs over much of Africa, Europe, India, and the Middle East; whereas Rocky Mountain Spotted Fever (RMSF) is commonly found throughout Canada, parts of Central and South America, and the US.
Crimean-Congo hemorrhagic Fever (CCHF) is a rare but serious viral disease transmitted by tick bites or contact with infected animal blood. It is the most widespread viral hemorrhagic fever, found in Eastern and Southern Europe, the Mediterranean, northwestern China, central Asia, Africa, the Middle East, and the Indian subcontinent. Healthcare workers and those handling livestock face higher risk.
The key to prevent tick-borne diseases is to protect yourself from tick bites (see also fact-sheet "Mosquito and tick bite prevention"):
The best prevention against tick-borne encephalitis (TBE) is to get vaccinated; this is recommended if living or travelling in an endemic area. The vaccine protects against all virus subtypes.
Informazioni generali influenza stagionale (influenza)
Consultare i seguenti link dell'UFSP:
There is a risk of arthropod-borne diseases other than malaria, dengue, chikungunya or zika in sub-/tropical regions, and some areas of Southern Europe. These include the following diseases [and their vectors]:
Wichtig: Eine STI kann auch ohne oder mit nur leichten Symptomen auftreten. Auch wenn Sie sich dessen nicht bewusst sind, können Sie andere anstecken. Deshalb ist es wichtig sich testen zu lassen.
Durch Bakterien oder Parasiten hervorgerufen
Alle diese Krankheiten können geheilt werden. Wichtig ist dabei, frühzeitig zu testen und umgehend zu therapieren, um Komplikationen und v.a. weitere Übertragungen zu vermeiden.
Durch Viren hervorgerufen
Il vaiolo è stato riscontrato comunemente in Africa occidentale e centrale per molti anni, dove il presunto serbatoio - i piccoli mammiferi - è endemico. Esistono due tipi di virus del vaiolo delle scimmie, chiamati "cladi", che causano la malattia: il clade I in Africa centrale e il clade II in Africa occidentale. Dalla fine delle campagne di vaccinazione contro il vaiolo all'inizio degli anni '80, i casi di vaiolo sono aumentati, all'inizio lentamente e negli ultimi 5-10 anni in modo significativo, soprattutto nella Repubblica Democratica del Congo (RDC).
Nel 2022, una nuova sottoclade emergente del clade II è stata responsabile di un'epidemia globale che si è diffusa principalmente attraverso il contatto sessuale tra uomini che hanno rapporti sessuali con uomini. Ne è scaturita la prima emergenza sanitaria pubblica di interesse internazionale (PHEIC) dichiarata dall'OMS fino al 2023. Sebbene l'epidemia del clade II sia ora sotto controllo, continua a circolare in tutto il mondo.
Nel 2024, la continua diffusione dell'mpox clade I nelle regioni endemiche dell'Africa centrale, in particolare nella RDC, e l'emergere di una nuova sottoclade Ib nell'est della RDC e nei Paesi limitrofi hanno destato preoccupazione a livello globale e hanno spinto l'OMS a dichiarare una PHEIC per la seconda volta in due anni. L'attuale diffusione geografica della variante mpox clade Ib avviene per vie commerciali attraverso il contatto sessuale (ad esempio, le lavoratrici del sesso), seguita dalla trasmissione locale nelle famiglie e in altri ambienti (che sta diventando sempre più importante).
Trasmissione da animale a uomo
L'Mpox può diffondersi dall'animale all'uomo quando questi entra in contatto diretto con un animale infetto (roditori o primati).
Trasmissione da uomo a uomo
Il vaiolo si può diffondere da persona a persona attraverso uno stretto contatto fisico (sessuale e non) con una persona che presenta i sintomi del vaiolo. Le lesioni della pelle e delle mucose, i fluidi corporei e le croste sono particolarmente contagiosi. Una persona può infettarsi anche toccando o maneggiando indumenti, lenzuola, asciugamani o oggetti come utensili/piatti per mangiare che sono stati contaminati dal contatto con una persona con i sintomi. I membri della famiglia, gli assistenti familiari e i partner sessuali di un caso confermato di mpox sono a maggior rischio di infezione, così come gli operatori sanitari che trattano un caso senza un'adeguata protezione personale.
Il periodo di incubazione (tempo che intercorre tra l'infezione e la comparsa dei sintomi) varia da pochi giorni a 3 settimane. La Mpox provoca un'eruzione cutanea che può essere dolorosa, associata a linfonodi ingrossati e febbre. La febbre può iniziare già prima della fase esantematica. Altri sintomi includono dolori muscolari, mal di schiena e affaticamento. L'eruzione cutanea può essere localizzata o generalizzata, con poche o centinaia di lesioni cutanee. Colpisce principalmente il viso, il tronco, i palmi delle mani e le piante dei piedi. Può essere presente anche nelle aree genitali e sulle membrane mucose come la bocca e la gola. I sintomi durano in genere dalle 2 alle 4 settimane e la persona rimane contagiosa fino alla guarigione di tutte le lesioni (una volta cadute le cabine).
Le complicazioni includono infezioni batteriche secondarie, infezioni polmonari e cerebrali e coinvolgimento di altri organi, parto prematuro e altro. I bambini, le donne in gravidanza e le persone con un sistema immunitario debole sono più a rischio di sviluppare una forma grave di mpox.
La maggior parte delle persone affette da mpox guarisce spontaneamente e non necessita di un trattamento antivirale specifico. La gestione dell'assistenza consiste nell'alleviare il dolore e gli altri sintomi e nel prevenire le complicazioni (ad esempio, la superinfezione). Diversi trattamenti antivirali sono studiati in vari Paesi e possono essere utilizzati in studi o in situazioni cliniche secondo le raccomandazioni delle società mediche nazionali.
In caso di sintomi:
Precauzioni generali:
Vaccinazione:
Esistono diversi vaccini contro il vaiolo (ad esempio Jynneos®, produzione Bavarian Nordic). Il vaccino Bavarian Nordic è stato originariamente sviluppato per combattere il vaiolo, ma offre una protezione incrociata contro il vaiolo. In Svizzera, il vaccino Jynneos® è autorizzato da Swissmedic dal 2024. I gruppi a rischio (ad esempio, gli uomini che hanno rapporti sessuali con altri uomini o le persone transgender con più partner sessuali) possono essere vaccinati dal 2022 e questa raccomandazione rimane invariata (vedi raccomandazioni dell'UFSP). Alla luce della situazione epidemiologica in Africa nel 2024, il Comitato svizzero di esperti in medicina dei viaggi raccomanda la vaccinazione contro l'mpox per i professionisti che sono/saranno in contatto con pazienti sospetti di mpox in regioni endemiche/epidemiche o che lavorano in un laboratorio in cui è presente il virus (per gli aggiornamenti, vedi news).
Il rischio per la popolazione generale e per i viaggiatori (turisti) è considerato estremamente basso se vengono seguite le precauzioni generali di cui sopra e se la vaccinazione non è raccomandata.
0